Kevin Marks (L) and David Schenkein, GV

Ex­clu­sive: GV’s David Schenkein turns to a fa­mil­iar face at No­var­tis for his lat­est re­cruit as en­tre­pre­neur-in-res­i­dence

David Schenkein has added a new mem­ber to GV’s still quite ex­clu­sive club of biotech CEOs-in-wait­ing. And this time the Google Ven­tures play­er is turn­ing to some­one he’d worked with for years at Agios, the com­pa­ny he built from a white sheet of pa­per.

Schenkein re­cruit­ed Kevin Marks out of NI­BR, where he’s been work­ing as head of the on­col­o­gy dis­cov­ery group. But be­fore join­ing Jay Brad­ner’s dis­cov­ery crew in the fall of 2020, Marks had spent close to 12 years at Agios, in­clud­ing a broad swath of time that over­lapped with Schenkein’s decade-long run as CEO, which was lat­er su­per­seded by an on­go­ing stretch as chair­man of the board.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.